{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:45:41Z","timestamp":1763664341090,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:02:00Z","timestamp":1595721720000},"page":"825-835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?"],"prefix":"10.1016","volume":"34","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.hoc.2020.06.001_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2020.06.001_bib2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.hoc.2020.06.001_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jncimonographs\/lgu007","article-title":"Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Smedby","year":"2014","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.001_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.001_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.001_bib6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The mantle cell lymphoma international prognostic index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.001_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study","volume":"166","author":"Nordstrom","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.001_bib8","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/ijc.26491","article-title":"Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma","volume":"131","author":"Holtan","year":"2012","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.001_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ijc.24830","article-title":"Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study","volume":"126","author":"Thompson","year":"2010","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.001_bib10","first-page":"237","article-title":"Dietary phytocompounds and risk of lymphoid malignancies in the California Teachers Study cohort","volume":"22","author":"Chang","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.001_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3109\/10428191003690364","article-title":"Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women","volume":"51","author":"Han","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.001_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s004280000284","article-title":"Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome","volume":"437","author":"Molina","year":"2000","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.001_bib13","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/10428190410001723331","article-title":"The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients","volume":"45","author":"Matutes","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.001_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/10428190127511","article-title":"Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma","volume":"42","author":"Yoong","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.001_bib15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2020.06.001_bib16","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.001_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/exd.12527","article-title":"Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II","volume":"23","author":"Fu","year":"2014","journal-title":"Exp Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.001_bib18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.hoc.2020.06.001_bib19","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.001_bib20","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.001_bib21","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"45","key":"10.1016\/j.hoc.2020.06.001_bib22","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.06.001_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.gene.2017.06.056","article-title":"Histone H3 lysine 4 methyltransferase KMT2D","volume":"627","author":"Froimchuk","year":"2017","journal-title":"Gene"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.001_bib24","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.001_bib25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.001_bib26","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.001_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood-2019-129323","article-title":"Minimal residual disease (MRD) assessment in the ECOG1411 randomized phase 2 trial of front-line bendamustine-rituximab (BR)-Based Induction Followed By Rituximab (R) \u00b1 Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.001_bib28","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/- monocytes in B-cell non-hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.001_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.12531","article-title":"Absolute monocyte count at diagnosis and survival in mantle cell lymphoma","volume":"163","author":"Porrata","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.001_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12409","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"162","author":"von Hohenstaufen","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.001_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.001_bib32","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.23838","article-title":"Elevated soluble IL-2Ralpha, IL-8, and MIP-1beta levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma","volume":"89","author":"Sonbol","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.001_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13073-016-0301-4","article-title":"Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection","volume":"8","author":"Montassier","year":"2016","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.001_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/apt.13302","article-title":"Chemotherapy-driven dysbiosis in the intestinal microbiome","volume":"42","author":"Montassier","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.hoc.2020.06.001_bib35","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fonc.2018.00556","article-title":"Metabolic reprogramming of non-Hodgkin's B-cell lymphomas and potential therapeutic strategies","volume":"8","author":"Ricci","year":"2018","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.001_bib36","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1158\/1541-7786.MCR-18-0256","article-title":"Metabolic detection of bruton's tyrosine kinase inhibition in mantle cell lymphoma cells","volume":"17","author":"Lee","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"491","key":"10.1016\/j.hoc.2020.06.001_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"27","key":"10.1016\/j.hoc.2020.06.001_bib38","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.hoc.2020.06.001_bib39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.06.001_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ajh.25493","article-title":"Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma","volume":"94","author":"St-Pierre","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.001_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2967\/jnumed.116.173542","article-title":"18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab","volume":"58","author":"Lamonica","year":"2017","journal-title":"J\u00a0Nucl Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:06Z","timestamp":1760184846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300642"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}